Investment Thesis
Merck & Co. is positioned to capitalize on secular trends in Healthcare. Our analysis suggests the market is underappreciating the margin expansion story.
[Source: Generated via Semantic Analysis of MRK 10-K filings]
Financial Summary (USD Millions)
| Fiscal Year |
2023A |
2024A |
2025E |
| Revenue |
583.8 |
623.86 |
666.67 |
| EBITDA |
57.22 |
47.69 |
63.84 |
| Net Income |
18.82 |
11.08 |
20.49 |
| EPS |
18.82 |
11.08 |
20.49 |
Valuation Methodology
Our valuation is derived from a 10-year DCF model using a WACC of 10.7% and a terminal growth rate of 2.5%. We also consider EV/EBITDA multiples relative to the Healthcare peer group.
Key Risks
- Cyclical downturn in Healthcare.
- Regulatory changes affecting margins.
- Execution risk on new product launches.
AUDIT TRAIL
Model ID: 03b3fa0d-c648-43f9-9401-77f8dc9a8c27
Version: FinGPT-v4.2
Training Cutoff: 2025-10-31
Compliance Check: PASS
Processing Time: 207ms
Disclaimer: This report is generated by an autonomous AI system for informational purposes only. It does not constitute financial advice. Past performance is not indicative of future results.